ClinicalTrials.gg
Not yet recruitingNCT07311967UFPUpdated Dec 31, 2025

Short-Term Health Outcomes of Cooking UFP Exposure

An interventional study of Clean Indoor Air Exposure (Control) and Exposure to Cooking-Generated Ultrafine Particles and Gases in Cognitive Function Decline, Air Pollution Exposure and Respiratory Inflammation, sponsored by University of Illinois at Chicago. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Signs and Symptoms, Respiratory with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Signs and Symptoms, Respiratory · United States.

Planned enrollment
14th of 14
15 · median 129
Started
2026
the only one that year
No phase
9 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Signs and Symptoms, Respiratory with a site in United States, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 16th registered.

Signs and Symptoms, Respiratory

64 studies on the registry are indexed under Signs and Symptoms, Respiratory; 9 are open to participants now.

Browse Signs and Symptoms, Respiratory studies →

Open to participants now

2 of the 17 studies in Signs and Symptoms, Respiratory with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Signs and Symptoms, Respiratory studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Signs and Symptoms, Respiratory with a site in United States, or all of them as a file.
02

Study summary

This study examines the short-term respiratory and cognitive effects of exposure to ultrafine particles (UFPs) generated during typical household cooking. Healthy adults will complete two 6-hour sessions in a controlled exposure chamber at the University of Illinois Chicago: one control day with clean indoor air and one exposure day during which standardized cooking (frying potatoes and grilling beef) is performed by research staff. Participants will not cook or handle food. Lung function will be measured using peak expiratory flow (PEF), and cognitive performance will be assessed using validated tests including the Hopkins Verbal Learning Test-Revised and the Processing Speed Index from the WAIS-IV. Airborne particle and gas concentrations in the chamber will be continuously monitored to ensure that exposures remain within levels typical of everyday home cooking. Findings will help characterize acute physiological responses to indoor cooking emissions and inform future research on indoor air quality and potential mitigation strategies.

Read the detailed description

This study evaluates the short-term respiratory and cognitive responses to controlled exposure to cooking-generated ultrafine particles (UFPs). Cooking emissions are one of the most common sources of indoor particulate pollution, yet their acute physiological effects remain poorly characterized. To address this gap, the study uses a controlled exposure chamber environment that reproduces typical household cooking conditions while allowing precise measurement of airborne particle and gas concentrations.

Healthy adult volunteers will participate in two study sessions conducted on consecutive days. On the exposure day, research staff will prepare a standardized meal (frying potatoes and grilling beef) inside the chamber to generate UFPs and co-emitted gases at levels representative of home cooking. On the control day, participants remain in the same chamber but without any cooking activity. Participants will spend approximately six hours in the chamber each day and will remain at rest except during scheduled assessments.

The study employs a randomized two-period crossover design so each participant serves as their own control. Lung function and cognitive performance are assessed multiple times on each day using validated instruments. Air quality is monitored continuously using particle sizing instruments, particle mass monitors, and a gas analyzer to characterize exposure conditions. Pre-defined stopping rules and ventilation procedures are implemented if concentrations exceed levels typical of household cooking.

This study is designed to generate preliminary U.S.-based data on the immediate effects of cooking-related UFP exposure on respiratory function and cognitive performance. Findings will help define exposure-response patterns, support future NIH and American Lung Association proposals, and improve understanding of indoor air quality impacts in everyday environments.

03

Conditions studied

  • Cognitive Function Decline
  • Air Pollution Exposure
  • Respiratory Inflammation

Keywords

  • Cooking emissions
  • Neurocognitive function
  • Respiratory symptoms
  • Ultrafine particles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults 18 years of age or older

Able to understand and speak English sufficiently to complete cognitive testing

Able and willing to complete two consecutive study sessions lasting approximately 6 hours each

Able to avoid cooking, toasting, and fume-generating household activities (e.g., strong cleaning products, ironing, hair drying) for 24 hours before each session

Able to avoid tobacco, marijuana, vaping, and alcohol use as specified in the study protocol

Able to provide

Exclusion criteria

Exclusion Criteria

Younger than 18 years old

Pregnant or planning pregnancy during study participation

Current smoking or use of:

Cigarettes

E-cigarettes or vaping devices

Marijuana

Shisha/hookah

Binge drinking, heavy alcohol use, or inability to abstain from alcohol for 24 hours before study visits

Restaurant chefs or individuals who perform frequent commercial-level cooking

Individuals who cook two or more frying or grilling meals per day at home

Cooking anxiety or mageirocophobia

Any diagnosed neurological disease, including stroke, seizure disorder, multiple sclerosis, traumatic brain injury, dementia, or similar conditions

Any significant respiratory disease, including:

(COPD)

Untreated severe asthma

Chronic bronchitis or other major lung disease

Any significant psychiatric condition, including:

Schizophrenia spectrum disorder

Untreated substance use disorder

Severe mood disorder

Severe anxiety disorder

Claustrophobia or anxiety in enclosed spaces (if severe enough to interfere with chamber procedures)

Inability to comply with study procedures or safety requirements

Any medical or psychological condition that, in the judgement of the investigators, may increase risk or interfere with study participation

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Other
    Control Condition (Clean Indoor Air)

    Participants will complete a control study session conducted in a controlled exposure chamber with clean indoor air and no cooking activity. Respiratory, cognitive, and physiological outcomes will be assessed during the session.

    Other: Clean Indoor Air Exposure (Control)

  • Experimental
    Cooking Emissions Exposure

    Participants will complete an exposure study session conducted in the same controlled exposure chamber during which cooking activities generate ultrafine particles. Respiratory, cognitive, and physiological outcomes will be assessed during the session.

    Other: Exposure to Cooking-Generated Ultrafine Particles and Gases

Interventions

  • OtherClean Indoor Air Exposure (Control)

    Participants will be exposed to clean indoor air in a controlled exposure chamber with no cooking activity. This condition serves as the control session for within-subject comparisons.

  • OtherExposure to Cooking-Generated Ultrafine Particles and Gases

    Participants will be exposed to cooking-generated ultrafine particles and associated gases in a controlled exposure chamber during standardized cooking activities.

06

What researchers measure

Primary outcomes

  1. Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall Score

    Cognitive performance related to verbal memory will be assessed using the Hopkins Verbal Learning Test-Revised (HVLT-R). The primary metric will be the change in HVLT-R Total Recall Score between exposure and control conditions, calculated from repeated assessments to evaluate short-term cognitive effects of ultrafine particle exposure.

    Time frame: Measured at baseline and at approximately 1, 2, 3, and 5 hours after session start on both study days

  2. Change in Peak Expiratory Flow (PEF)

    Peak Expiratory Flow (PEF) will be measured using a handheld peak flow meter to assess short-term changes in lung function following exposure to cooking-generated ultrafine particles compared with the clean-air control day. Changes are evaluated within subjects using repeated measurements across both conditions.

    Time frame: Measured at baseline and at approximately 1, 2, 3, and 5 hours after session start on both study days

  3. Change in WAIS Symbol Search Raw Score

    Cognitive performance related to processing speed and visual attention will be assessed using the Symbol Search subtest of the Wechsler Adult Intelligence Scale (WAIS). The primary metric will be the change in WAIS Symbol Search raw score between exposure and control conditions, calculated from repeated assessments to evaluate short-term cognitive effects of ultrafine particle exposure.

    Time frame: Measured at baseline and at approximately 1, 2, 3, and 5 hours after session start on both study days

Secondary outcomes

  1. Ultrafine Particle Number Size Distribution in particles/cm3

    Ultrafine particle number size distributions will be measured using a Scanning Mobility Particle Sizer (SMPS) and Partector 2 Pro. These measurements characterize exposure conditions and allow correlation with physiological responses.

    Time frame: Continuously measured average concentration with one minute intervals during each study session on control and exposure days, from session start to session end (approximately 5 hours per session), across both study periods.

  2. Fine Particle Mass Concentrations (PM2.5) in microgram/cm3

    Particle mass concentrations (PM2.5) will be measured using a DustTrak DRX monitor to quantify particulate exposure profiles during cooking and control sessions. These measurements characterize exposure conditions and allow correlation with physiological responses.

    Time frame: Continuously measured average concentration with one minute intervals during each study session on control and exposure days, from session start to session end (approximately 5 hours per session), across both study periods

  3. Total Volatile Organic Compound (VOC) concentration in ppm

    Concentrations of over 50 volatile organic compounds (VOCs) will be monitored using FTIR spectroscopy (Gasmet DX4040) to characterize exposure to total VOC concentration during cooking. The concentration of individual gases will be add up to quantify total VOC concentration.

    Time frame: Continuously measured average concentration with one minute intervals during each study session on control and exposure days, from session start to session end (approximately 5 hours per session), across both study periods

  4. CO2 concentration in ppm

    Description: Concentrations of CO2 will be monitored using Atmocube, Atmo, USA instrument. This measurement characterize exposure conditions and allow correlation with physiological responses.

    Time frame: Continuously measured average concentration with one minute intervals during each study session on control and exposure days, from session start to session end (approximately 5 hours per session), across both study periods

  5. CO concentration in ppm

    Description: Concentrations of CO will be monitored using FTIR spectroscopy (Gasmet DX4040) to characterize exposure to CO during cooking. The

    Time frame: Continuously measured average concentration with one minute intervals during each study session on control and exposure days, from session start to session end (approximately 5 hours per session), across both study periods

  6. NO2 concentration in ppm

    Concentrations of NO2 will be monitored using FTIR spectroscopy (Gasmet DX4040) to characterize exposure to NO2 during cooking.

    Time frame: Continuously measured average concentration with one minute intervals during each study session on control and exposure days, from session start to session end (approximately 5 hours per session), across both study periods

Other outcomes

  1. Temperature Condition in Exposure Chamber

    Ambient temperature will be recorded to ensure environmental conditions remain consistent and to support interpretation of particle behavior.

    Time frame: Continuously measured average concentration with one minute intervals during each study session on control and exposure days, from session start to session end (approximately 5 hours per session), across both study periods

  2. Number of Participants Reporting Acute Symptoms During Study Sessions

    Participant-reported symptoms related to tolerability of the study procedures and exposure will be assessed using a standardized symptom checklist administered by study staff. Symptoms assessed will include throat or eye irritation, cough, headache, dizziness, and nausea. The outcome measure will be the number of participants reporting one or more symptoms during each study session.

    Time frame: Assessed at baseline and at approximately 1, 2, 3, and 5 hours after session start on control and exposure days

  3. Relative Humidity Condition in Exposure Chamber

    Relative Humidity in the chamber will be recorded to ensure environmental conditions remain consistent and to support interpretation of particle behavior.

    Time frame: Continuously measured average concentration with one minute intervals during each study session on control and exposure days, from session start to session end (approximately 5 hours per session), across both study periods

07

Study locations

1 site
  • UIC
    Chicago, Illinois 60612, United States
    • Mehdi Amouei Torkmahalleh, PhD · Contactmehdiat@uic.edu · 8326077765
    • Kyle J. Jennette, PhD · Sub investigator
    • Leonard H. Go, MD · Sub investigator
    • Rachel Lane, M.Sc. · Sub investigator
    • Mahsa Alishiri, M.Sc. · Sub investigator
    • Emani Cotton, B.Sc. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this study does not collect biospecimens and all data are used solely for the analyses specified in the protocol. Data are stored in coded form and are not intended for secondary research use. In addition, screening data for ineligible individuals are destroyed within 3 days, and no identifiable information is retained beyond what is required for regulatory documentation. Only aggregate, de-identified results may be shared with participants upon request, but individual-level datasets will not be made available to external researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Mar 2026, 1 month later.

Of 18 interventional studies with no phase under Signs and Symptoms, Respiratory, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Dec 31, 2025
StartEst.
Jan 2, 2026
Primary completionEst.
Mar 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07311967
Responsible party
Mehdi Amouei Torkmahalleh (Assistant Professor, University of Illinois at Chicago) — Principal investigator
First posted
Dec 31, 2025
Start date
Jan 2, 2026 (estimated)
Primary completion
Mar 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

Mehdi Amouei Torkmahalleh, PhD
Contact
mehdiat@uic.edu
8326077765
Mehdi Amouei Torkmahalleh, PhD
principal investigator · University of Illinois at Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion